IDEAYA Biosciences Announces Agenda for 10-Year Anniversary R&D Day on September 8, 2025
IDEAYA Biosciences (NASDAQ:IDYA) will host its 10-Year Anniversary R&D Day on September 8, 2025 in New York from 8:00-10:30am EST. The event will showcase the company's progress and future growth strategy, featuring presentations on multiple clinical programs.
Key highlights include new clinical data presentations on darovasertib in neoadjuvant uveal melanoma, IDE849 (DLL3 TOP1 ADC), and IDE397 (MAT2A). Dr. Arun D. Singh from Cleveland Clinic will present Phase 2 trial data of darovasertib and discuss the Phase 3 OptimUM-10 trial design. The agenda also covers IDE892 (PRMT5) development and the company's AI/ML discovery capabilities.
IDEAYA Biosciences (NASDAQ:IDYA) organizzerà il suo R&D Day per il 10° anniversario il 8 settembre 2025 a New York dalle 8:00 alle 10:30 EST. L'evento metterà in mostra i progressi dell'azienda e la strategia di crescita futura, con presentazioni su diversi programmi clinici.
I punti salienti comprendono nuove presentazioni di dati clinici su darovasertib nel melanoma uveale in neoadiuvante, IDE849 (DLL3 TOP1 ADC) e IDE397 (MAT2A). Il dott. Arun D. Singh della Cleveland Clinic presenterà i dati della fase 2 su darovasertib e discuterà il disegno dello studio di fase 3 OptimUM-10. L'agenda include inoltre lo sviluppo di IDE892 (PRMT5) e le capacità di discovery basate su AI/ML dell'azienda.
IDEAYA Biosciences (NASDAQ:IDYA) celebrará su R&D Day por el 10.º aniversario el 8 de septiembre de 2025 en Nueva York de 8:00 a 10:30 a.m. EST. El evento mostrará los avances de la compañía y su estrategia de crecimiento futuro, con presentaciones sobre varios programas clínicos.
Los puntos clave incluyen nuevas presentaciones de datos clínicos sobre darovasertib en melanoma uveal neoadyuvante, IDE849 (DLL3 TOP1 ADC) y IDE397 (MAT2A). El Dr. Arun D. Singh de la Cleveland Clinic presentará los datos del ensayo de fase 2 de darovasertib y discutirá el diseño del ensayo de fase 3 OptimUM-10. La agenda también abarca el desarrollo de IDE892 (PRMT5) y las capacidades de descubrimiento por IA/ML de la compañía.
IDEAYA Biosciences (NASDAQ:IDYA)는 2025년 9월 8일 오전 8시부터 10시 30분(동부표준시)까지 뉴욕에서 10주년 R&D 데이를 개최합니다. 본 행사는 회사의 진행 상황과 향후 성장 전략을 소개하며 여러 임상 프로그램에 대한 발표가 진행됩니다.
주요 내용으로는 신보조요법(네오애주번트) uveal melanoma에서의 darovasertib, IDE849 (DLL3 TOP1 ADC), IDE397 (MAT2A)에 대한 새로운 임상 데이터 발표가 포함됩니다. 클리블랜드 클리닉의 Arun D. Singh 박사가 darovasertib의 2상 시험 데이터를 발표하고 3상 OptimUM-10 시험 설계에 대해 논의할 예정입니다. 아젠다에는 IDE892 (PRMT5) 개발과 회사의 AI/ML 기반 신약 발굴 역량도 포함됩니다.
IDEAYA Biosciences (NASDAQ:IDYA) organisera sa journée R&D pour le 10e anniversaire le 8 septembre 2025 à New York de 8h00 à 10h30 EST. L'événement mettra en avant les progrès de la société et sa stratégie de croissance future, avec des présentations sur plusieurs programmes cliniques.
Les points forts incluent de nouvelles présentations de données cliniques sur darovasertib en néoadjuvant pour le mélanome uvéal, IDE849 (DLL3 TOP1 ADC) et IDE397 (MAT2A). Le Dr Arun D. Singh de la Cleveland Clinic présentera les données de l'essai de phase 2 sur darovasertib et discutera de la conception de l'essai de phase 3 OptimUM-10. L'ordre du jour couvre également le développement d'IDE892 (PRMT5) et les capacités de découverte en IA/ML de la société.
IDEAYA Biosciences (NASDAQ:IDYA) wird am 8. September 2025 in New York von 8:00 bis 10:30 Uhr EST sein 10-jähriges R&D Day veranstalten. Die Veranstaltung präsentiert den Fortschritt des Unternehmens und die künftige Wachstumsstrategie und enthält Vorträge zu mehreren klinischen Programmen.
Zu den Highlights gehören neue klinische Daten zu darovasertib in neoadjuvanter Uveamelanom, IDE849 (DLL3 TOP1 ADC) und IDE397 (MAT2A). Dr. Arun D. Singh von der Cleveland Clinic wird die Daten der Phase-2-Studie zu darovasertib vorstellen und das Design der Phase-3-Studie OptimUM-10 erörtern. Die Agenda behandelt außerdem die Entwicklung von IDE892 (PRMT5) sowie die AI/ML-gestützten Discovery-Fähigkeiten des Unternehmens.
- None.
- None.
Members of IDEAYA's senior leadership team will provide an overview of the company's progress to date, including presentation of new clinical data on darovasertib in neoadjuvant uveal melanoma (UM), IDE849 (DLL3 TOP1 ADC) and IDE397 (MAT2A), and outline key areas of focus as part of their future growth strategy. Details of the R&D Day agenda are below.
Agenda topics
- IDEAYA 10-Year Anniversary and R&D Day Introduction
- Darovasertib (PKC)
- Phase 2 Neoadjuvant UM Data in Plaque Brachytherapy-eligible Patients
- IDE849 (DLL3 TOP1 ADC)
- Phase 1 SCLC Data from the 2025 World Conference on Lung Cancer (WCLC)
- Mechanistic Data from 2025 WCLC to Support Combination of TOP1-ADCs with IDE161/PARG
- IDE397 (MAT2A)
- Combination Rationale with Trodelvy (TROP2 TOP1 ADC) in MTAP-deletion solid tumors
- Initial Phase 1 Clinical Data from IDE397/Trodelvy Combination in MTAP-deletion urothelial cancer
- IDE892 (PRMT5)
- Potentially Best-in-Class PRMT5 Profile and Combination Opportunity with IDE397 (MAT2A) in MTAP-deletion solid tumors
- Application of AI/ML in Our Discovery Capabilities
- Closing Remarks and Q&A
Joining IDEAYA's leadership team at the R&D Day will be Dr. Arun D. Singh, Director of the Department of Ophthalmic Oncology at the Cole Eye Institute, Cleveland Clinic. Dr. Singh will present data from IDEAYA's Phase 2 trial of darovasertib in the neoadjuvant setting of UM and discuss the design and objectives of IDEAYA's recently initiated Phase 3 OptimUM-10 trial to support a potential approval in this indication.
A live question and answer session will follow the presentation. Registration for this event can be accessed here or through the IDEAYA website https://ir.ideayabio.com/events.
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease. We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications. Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.
Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to participation in and/or presentation at a certain investor relation event. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's current and future filings with the
Investor and Media Contact
IDEAYA Biosciences
Joshua Bleharski, Ph.D.
Chief Financial Officer
investor@ideayabio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-agenda-for-10-year-anniversary-rd-day-on-september-8-2025-302531447.html
SOURCE IDEAYA Biosciences, Inc.
FAQ
When and where is IDEAYA Biosciences (IDYA) hosting its R&D Day 2025?
What clinical data will be presented at IDEAYA's (IDYA) R&D Day 2025?
Who is the key opinion leader presenting at IDEAYA's (IDYA) R&D Day?
How can investors access IDEAYA's (IDYA) R&D Day presentation?
